Epsilogen has completed the acquisition of TigaTx, combining their expertise in IgE antibodies with TigaTx's IgA antibody platform to create the world's first pan-isotype cancer antibody company.
Epsilogen secured additional funding of £12.5m in Series B expansion, bringing the total to £43.25m, to support clinical development of its IgE antibody pipeline.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.